ANPD-001 is under clinical development by Aspen Neuroscience and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANPD-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ANPD-001 overview

ANPD-001 is under development for the treatment of sporadic Parkinson’s disease. The therapy comprised of autologous induced pluripotent stem cells obtained from the skin fibroblasts which are transformed into dopamine secreting neurons. The drug candidate is being developed based on iPSC platform. It is administered through parenteral route.

Aspen Neuroscience overview

Aspen Neuroscience is a biotechnology company that discovers and develops iPSC (induced pluripotent stem cell) derived personalized cell replacement therapies to treat neurological indications. It is investigating its lead product candidate ANPD001, an autologous neuron replacement therapy for sporadic Parkinson’s disease; and ANPD002, a gene-corrected autologous neuron replacement therapy against genetic variants that increase the risk of Parkinson’s disease. The company’s technology combines stem cell biology with artificial intelligence and genomic approaches to discover patient-specific, restorative treatments. It was funded by Arch Venture Partners, Frazier Healthcare Partners, Axon Ventures, and Domain Associates, among others. Aspen Neuroscience is headquartered in San Diego, California, the US.

For a complete picture of ANPD-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.